NeuroPace (Nasdaq:NPCE) announced today that it appointed Brett Wingeier as its new VP of R&D and Katie Keller as VP of marketing.
Both appointments made by the maker of the FDA-approved RNS system for treating epilepsy go into effect immediately.
Wingeier’s experience includes a stint as co-founder, CTO and CEO of Magnus Medical, another neurostimulation company. Keller, meanwhile, led global commercial marketing for Boston Scientific’s deep brain stimulation (DBS) franchise.
“We are excited to welcome Katie and Brett to our team. Katie brings an understanding of the neurostimulation market and expertise in market development through her tenure at Boston Scientific and leading its DBS commercial marketing function. I’m confident that through her leadership our market development programs and plans will move to the next level as we look to close the treatment gap by driving broader adoption and utilization of RNS therapy,” said Joel Becker, CEO of NeuroPace. “Brett is a proven innovator and developer of advanced medical devices, which includes our RNS technology. His extensive knowledge of the RNS System and epilepsy will position him to help advance our strategy to expand the capabilities of the RNS System through our technology development plans and pipeline.”
More about the new VPs at NeuroPace
Keller offers a track record of success in medical device marketing and commercial roles, according to a news release. Most recently, she led the global commercial marketing function for the Boston Scientific DBS franchise, but she also spent time in leadership roles within a number of device markets. Those include interventional cardiology, cardiac physiology and cardiac rhythm management.
“I am excited to join NeuroPace and look forward to working with the team on expanding access to the Company’s life changing RNS therapy through indication expansion and increased awareness with both patients and clinicians,” said Keller.
Wingeier has more than 20 years of experience across neurotech, biomedical engineering and entrepreneurship. That includes contributing to the development of the NeuroPace RNS system as a principal engineer from 2001 to 2013. Most recently, he served as CEO, CTO and co-founder of Magnus Medical, helping to gain FDA clearance for a depression treatment. Before that, he also served in the same positions at Halo Neuroscience, another neuromodulation company.
“I am excited to rejoin NeuroPace at such an exciting time for the company and for the RNS system,” said Wingeier. “The unique monitoring and analysis capabilities of the RNS System have provided us with an unparalleled dataset. I look forward to working with the team and our customers to further evolve these capabilities and translate these data into enhanced ease of use, greater efficiency, and clinical insights that continue to transform the lives of people living with epilepsy.”
